HCA Healthcare, Inc. research snapshot
HCA AI stock analysis currently reads HCA Healthcare as a high-scale hospital and outpatient care operator with strong 2025 earnings, stable Q1 2026 revenue growth, and meaningful free cash flow, but also with elevated debt, labor-cost exposure, policy risk, and a chart that has not fully repaired. At the July 8, 2026 data cutoff, HCA traded near $423.10 with a verified market capitalization near $93.86 billion. The HCA AI stock forecast uses scenario ranges instead of a fixed price prediction because hospital volumes, payer mix, ACA exchange pressure, labor inflation, reimbursement rates, and leverage can change the earnings path quickly.
Current price
$423.10
Market cap
$93.86 billion verified market cap
AI score
73 / 100
Rating
Scaled hospital operator with durable demand, leverage, labor, and policy risk
Trend status
Recovering near the 50-day moving average, still below the 200-day moving average
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | HCA operates hospitals, surgery centers, emergency rooms, urgent care centers, physician clinics, and related care sites that patients and payers use for essential acute and outpatient care. | High |
| Moat | The moat comes from local market density, physician relationships, trauma and specialty capabilities, payer contracts, operating discipline, data scale, and capital access, but hospital markets remain competitive and regulated. | Medium-high |
| Management | CEO Sam Hazen has led HCA through capacity expansion, margin management, share repurchases, and technology investment, with the current test centered on labor, reimbursement, and balance-sheet discipline. | Medium-high |
| Financial trend | FY2025 revenue was $75.60 billion and net income attributable to HCA was $6.784 billion. Q1 2026 revenue rose 4.3% to $19.109 billion and diluted EPS rose 10.9% to $7.15. | High |
| Valuation | At $423.10, HCA screens near 14.55x TTM EPS, 1.23x sales, 11.84x free cash flow per share, and a 0.68% dividend yield using audited tool math. | High |
| Technical trend | The stock is near the 50-day moving average around $401.54, below the 200-day moving average around $459.97, and still below the March 2026 high zone. | Medium |
| Risk level | Main risks include labor cost inflation, payer mix deterioration, ACA and Medicaid policy changes, Medicare reimbursement pressure, uninsured care, cyber and compliance risk, debt, and capital spending needs. | Medium-high |
| AI confidence | Descriptive confidence is high because company and third-party data agree on key financials. Return confidence is lower because policy and reimbursement changes can reset estimates quickly. | High data confidence |
| Investment certainty | HCA has strong business quality, but the current setup needs sustained volume, payer stability, cost control, and a technical recovery above the 200-day moving average. | Medium |
HCA AI stock forecast
The HCA AI stock forecast is scenario-based because hospital earnings depend on admissions, acuity, labor costs, payer mix, reimbursement, ACA exchange exposure, debt cost, and capital spending. Using the $423.10 price reference, TTM EPS of $29.08, and an audited three-year model, the mechanical outcomes are about $658 in a bullish case, $471 in a base case, and $265 in a bearish case before dividends.
$620 to $665 before dividends
More likely if equivalent admissions grow, revenue per equivalent admission remains positive, labor costs stay controlled, ACA exchange pressure is offset, debt leverage stays manageable, and the market applies a high-teens earnings multiple to higher EPS.
$450 to $485 before dividends
More likely if EPS compounds at a mid-single-digit rate, 2026 guidance is met, volume growth is steady, the 200-day moving average is reclaimed, and investors value HCA near a mid-teens earnings multiple.
$250 to $285 before dividends
More likely if labor inflation, reimbursement pressure, Medicaid or ACA changes, uninsured care, debt costs, or weak volumes push earnings lower and the market compresses HCA toward a low-teens multiple.
HCA AI technical analysis
HCA AI technical analysis is mixed as of the July 8, 2026 data cutoff. StockAnalysis listed market cap near $93.86 billion, a 50-day moving average near $401.54, a 200-day moving average near $459.97, RSI near 67.06, and 20-day average volume near 1.55 million shares. MarketWatch reported a July 2 close at $410.50, still 26.24% below the March 12, 2026 52-week high of $556.52.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $423.10 | Price reference implied by the July 8, 2026 StockAnalysis market-cap snapshot and verified share-count math. |
| Immediate support | $410 to $411 | MarketWatch reported a July 2 close of $410.50 after a 4.39% rally, making this a recent close reference. |
| Deeper support | $400 to $405 | This area brackets the 50-day moving average near $401.54 and is the more important trend-support zone to watch. |
| Near resistance | $440 to $460 | This range sits between short-term rebound resistance and the 200-day moving average near $459.97. |
| Upper resistance | $550 to $557 | MarketWatch cited a March 12, 2026 52-week high of $556.52. This is an upper recovery reference, not a forecast. |
| Moving averages | 50-day near $401.54, 200-day near $459.97 | Price above the 50-day average but below the 200-day average supports a rebound, not a fully confirmed long-term uptrend. |
| Momentum | RSI near 67.06 | Momentum is positive and approaching overbought territory, so continuation needs volume and fundamental support. |
| Volume | 20-day average near 1.55 million shares | Volume confirmation matters around the July 24, 2026 estimated earnings date and reimbursement or policy headlines. |
| Volatility | Watch earnings, ACA pressure, labor commentary, and policy news | Hospital operators can gap on volume trends, wage inflation, payer mix, and regulatory updates. |
| Invalidation | Close below $400, then below $380 | A sustained break below the 50-day area weakens the rebound. A deeper break below the spring recovery base would challenge the larger setup. |
HCA AI trading strategy
The HCA AI trading strategy below is a rules-based research framework, not personal advice. It connects chart levels with hospital volume, payer mix, labor cost, ACA exchange exposure, capital spending, debt, and cash flow.
Watch for HCA to hold the $400 to $405 support area and move through $440 to $460 with improving volume, stable 2026 guidance, and no negative update on labor, payer mix, or ACA exchange pressure.
A failed move near the 200-day moving average followed by a close below $400 should reduce trend confidence, especially if Q2 commentary points to weaker admissions or cost pressure.
If HCA pulls back toward the 50-day average without a permanent earnings reset, compare the lower price with 2026 EPS guidance, free cash flow, debt, admissions, and peer action in Tenet and other hospital operators.
Do not treat a pullback as automatically attractive if reimbursement assumptions worsen, uninsured care rises, or labor cost pressure becomes structural.
Track equivalent admissions, revenue per equivalent admission, same-facility admissions, emergency visits, inpatient and outpatient surgeries, wage inflation, supply costs, debt, capex, buybacks, and payer-policy updates.
Position sizing should reflect that HCA can look statistically cheap before a reimbursement, labor, policy, or leverage reset becomes visible in reported EPS.
Investment research summary
Customers and payers fund HCA because communities need hospitals, emergency rooms, surgery centers, physician clinics, urgent care, diagnostics, and specialty care capacity. The business converts essential patient demand into facility revenue, operating margin, and cash flow.
The moat is strongest in local hospital networks, physician relationships, trauma and specialty capacity, payer contracting, regulatory know-how, operating scale, and clinical data. The moat can narrow if competitors expand outpatient sites or if payers gain pricing leverage.
The thesis fails if labor inflation outruns pricing, ACA or Medicaid economics worsen, Medicare reimbursement disappoints, uninsured care rises, debt limits flexibility, or capital spending does not translate into profitable patient volume.
Sam Hazen has emphasized volume growth, quality, margin discipline, capital investment, and shareholder returns. The key management test is balancing buybacks and capex against leverage and long-term capacity needs.
Hospital demand benefits from aging demographics, chronic disease, acuity, outpatient migration, and care-network density. The offset is that healthcare affordability keeps payer, employer, and government scrutiny high.
At $423.10, HCA is not priced like a hyper-growth healthcare stock, but it still assumes durable earnings, manageable debt, and no major policy reset. Margin of safety improves if free cash flow remains high and the stock stays near a mid-teens earnings multiple or lower.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $423.10 implied July 8, 2026 price reference | StockAnalysis HCA statistics | July 8, 2026 |
| Market capitalization | $93.86 billion, verified against 221.827 million shares | StockAnalysis HCA statistics | July 8, 2026 |
| FY2025 revenue | $75.600 billion | HCA Healthcare Q4 2025 results | July 8, 2026 |
| FY2025 net income attributable to HCA | $6.784 billion | HCA Healthcare Q4 2025 results | July 8, 2026 |
| Q1 2026 revenue and EPS | $19.109 billion revenue and $7.15 diluted EPS | HCA Healthcare Q1 2026 results | July 8, 2026 |
| Cash and total debt | $940 million cash and $48.023 billion total debt at March 31, 2026 | HCA Healthcare quarterly results | July 8, 2026 |
| Facility footprint | 189 hospitals and approximately 2,600 ambulatory sites of care | HCA Healthcare about page | July 8, 2026 |
| Valuation snapshot | 14.55x PE, 1.23x sales, 11.84x free cash flow | StockAnalysis HCA statistics | July 8, 2026 |
| Technical snapshot | 50-day MA $401.54, 200-day MA $459.97, RSI 67.06 | StockAnalysis HCA statistics | July 8, 2026 |
This HCA AI stock analysis is an informational research tool only. It is not investment advice, a rating, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available data as of July 8, 2026 and can be wrong if earnings, policy, reimbursement, labor costs, debt markets, or market sentiment change.
